Zobrazeno 1 - 3
of 3
pro vyhledávání: '"L. C. Iglesias Docampo"'
Autor:
J. Lambea Sorrosal, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, B. Cirauqui Cirauqui, A Lozano Borbalas, L. C. Iglesias Docampo, José A. Caballero, J Marruecos Querol, J M Ponce Ortega, M. Taberna Sanz, M. Plana Serrahima, I. Planas Toledano, E Ortega Izquierdo, Javier Martinez-Trufero, J C Adansa, I. Pajares Bernad, R. Mesia Nin, Jordi Rubió-Casadevall
Publikováno v:
Clinical and Translational Oncology. 23:1666-1677
Sequential treatment of Panitumumab (Pb) plus Paclitaxel (Px) as induction treatment (IT) followed by concurrent bioradiotherapy (Bio–RT) with Pb may be an alternative for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) in
Autor:
Antonio Rueda, B. Cirauqui Cirauqui, A. Carral Maseda, J. J. Lambea Sorrosal, J.J. Cruz Hernandez, V. Arrazubi Arrula, L. C. Iglesias Docampo, Y. Escobar, M. Pastor Borgoñón, N. Baste Rotllan
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Clinical & Translational Oncology
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Consejería de Sanidad de la Comunidad de Madrid
Clinical & Translational Oncology
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Head and neck cancer (HNC) is defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate evidence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c789eb5c1a24b3c6ce509594a6e4504c
https://hdl.handle.net/20.500.12530/29659
https://hdl.handle.net/20.500.12530/29659
Autor:
A. A. Rodriguez Garzotto A, L. C. Iglesias Docampo, C. Gravalos Castro, J. A. Lopez-Martin, T. Agullo Ortuno, V. Diaz Garcia, B. Homet, E. M. Ciruelos Gil, L. Manso, C. Mendiola, C. Gomez-Martin, R. Hitt, A. Gomez Camara, H. Cortes-Funes
Publikováno v:
Journal of Clinical Oncology. 29:e19671-e19671
e19671 Background: Molecular physiopathology of HFS induced by CAP is unclear. Interruption or dose reduction of CAP is the only effective strategy. Aims: to evaluate efficacy and safety of a topic...